## United States Senate

WASHINGTON, DC 20510

July 13, 2017

The Honorable Tom Price Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, D.C. 20201 Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

Dear Secretary Price and Administrator Verma:

We write today regarding the Centers for Medicare and Medicaid Services (CMS) regulations for Durable Medical Equipment (DME) in the Medicare program. Access to DME for Medicare beneficiaries is important to promote independence, manage chronic conditions, and improve overall well-being.

As you know, the Patient Protection and Affordable Care Act (P.L. 111-148) required CMS to establish adjusted fee schedules for DME in non-competitively bid areas and to consider the costs of furnishing services in these areas. We are concerned that CMS did not fully consider the costs of providing DME in non-competitively bid areas or the length of time needed by providers to adjust to the change.

To address these concerns, Congress included Section 16007 in the 21st Century Cures Act (P.L. 114-255), which delayed applying the second half of the adjustment for competitively bid prices in non-competitively bid areas through December 31, 2016. This provision also required the Department to study and report to Congress on how applying competitively bid prices in non-competitively bid areas affects beneficiary access to DME by January 12, 2017. To further address the unique challenges faced in non-competitively bid areas, Section 16008 requires the Department to take into account factors such as travel distance, cost of furnishing and servicing items, supply service and volume, and the number of suppliers in an area when determining future adjustments to competitive bidding prices.

While the delay directed by Congress was critical to avoid immediate disruptions in beneficiary access, lower reimbursement rates have now gone into effect. The language in the 21<sup>st</sup> Century Cures Act clearly demonstrates Congress' concern with the current reimbursement structure, and we request that the Department swiftly use its regulatory authority to provide further relief in non-competitively bid areas.

Thank you for your time and attention to this important matter. We look forward to your response.

Sincerely,

U.S. Senator

HEIDI HEITKAMP

U.S. Senator

LAMAR ALEXANDER U.S. Senator MICHAEL F. BENNET JOHN BARRASSO U.S. Senator U.S. Senator U.S. Senator SHELLOY MOORE C. RICHARD BURR U.S. Senator U.S. Senator THAD COCHRAN ROBERT P. CASEY JR U.S. Senator U.S. Senator SUSAN COLLINS U.S. Senator U.S. Senator STEVE DAINES U.\$. Senator U.S. Senator U.S. Senator CORY GARDNER JONI K. ERNST U.S. Senator U.S. Senator

| MAZIE K. HIRONO LLS. Senator  JOHNNY ISAKSON U.S. Senator  ANGUS S. KING JR. U.S. Senator |
|---|
| JAMES LANKFORD U.S. Senator  JOE MANCHIN III U.S. Senator                                 |
| JERRY MORAN U.S. Senator  RAND PAUL U.S. Senator  |
| JAMES RISCH U.S. Senator  M. MICHAEL ROUNDS U.S. Senator                                  |
|   |

BRIAN SCHATZ MARCO RUBIO U.S. Senator U.S. Senator RICHARD SHELBY JEANNE SHAHEEN U.S. Senator U.S. Senator LUTHER STRANGE DEBBIE STADI U.S. Senator U.S. Senator THOM TILLIS U.S. Senator Senator

U.S. Senator